启迪药业：控股股东所持公司股份被司法拍卖暨控制权拟发生变更

Core Viewpoint - The announcement by Qidi Pharmaceutical indicates a significant change in its shareholding structure due to a judicial auction, which will impact the company's control and governance [3]. Group 1: Financial Performance - For the year 2024, Qidi Pharmaceutical's revenue composition is as follows: Traditional Chinese medicine and health products account for 93.88%, while other products account for 6.12% [1]. Group 2: Shareholding Changes - On August 6, 2025, Qidi Pharmaceutical will transfer 58,606,962 shares from its controlling shareholder, Qidi Technology Service Co., Ltd., to Hunan Sailoxian Management Consulting Partnership, resulting in a decrease of Qidi Technology's shareholding from 26.37% to 1.90% [3]. - Hunan Sailoxian will acquire 58,606,962 shares, representing 24.47% of the total share capital of Qidi Pharmaceutical, marking a significant shift in ownership [3]. - This change in shareholding will not trigger a mandatory takeover bid but will lead to a change in control, significantly affecting the company's equity structure and governance [3].